Tirzepatide
GYMINDA
Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 285
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo + Tirzepatide | Obesity or overweight | n/r | 48 | n/r | n/r |
| RO7204239 low dose + Tirzepatide | Obesity or overweight | n/r | 48 | n/r | n/r |
| RO7204239 medium dose + Tirzepatide | Obesity or overweight | n/r | 48 | n/r | n/r |
| RO7204239 high dose + Tirzepatide | Obesity or overweight | n/r | 48 | n/r | n/r |